Business Wire

Shippeo Introduces Carbon Visibility and Brings Powerful New Features to Ocean and Road Visibility


Shippeo, a leading provider of global and multimodal shipment visibility, today announced new products and major platform enhancements, as part of their feature-packed 2022 Spring platform release. The updates focus on customer satisfaction, new innovations, performance, and meeting evolving market needs. A new CO2 emissions calculator provides critical information on carbon emissions and other greenhouse gasses from supply chain transport and distribution for shippers, logistics service providers and carriers. Container tracking using Shippeo’s Ocean Visibility solution is now faster and easier with a new user experience and powerful monitoring capabilities. In addition, timesaving usability enhancements, data quality improvements and ETA accuracy advancements are introduced for the company’s market-leading Road Visibility product. Finally with the migration to Google Cloud and Snowflake, significant performance and scalability upgrades are added to the Shippeo platform.

“Our latest Spring platform release is packed full of new features and capabilities for customers,” explains Anand Medepalli, Chief Product Officer at Shippeo, “including a completely new Carbon Visibility offering for accurately calculating CO2 and other greenhouse gas emissions at the shipment level, as well as major enhancements to our Ocean and Road visibility solutions. We are evolving our platform to not only meet the needs of our customers today, but also to solve tomorrow’s supply chain problems. This is the first release in a new twice-yearly Spring and Autumn Shippeo platform release cycle, representing a shift to more regular and regimented platform updates. This reliability and momentum will help us to keep ahead and continue to offer the most innovative real-time visibility platform experience for users, more powerful capabilities to increase productivity, and higher data quality to improve ROI for our customers.”

Accurate, consolidated CO2 emissions monitoring for shippers and carriers
Carbon Visibilityoffers shippers and logistics service providers a consolidated view of CO2 emissions for upstream and downstream transport and distribution activities in one place, bringing a number of new capabilities to help companies monitor progress towards sustainability objectives.

Carriers also benefit from the new Carbon Visibility offering, allowing them to avoid the time consuming manual work that they are faced with today to calculate emissions on behalf of their clients. Carriers can now use Shippeo to instantly generate CO2 emission reports, which should allow them to more easily allocate CO2 emissions from a single vehicle to multiple customers in LTL/groupage scenarios based on their business rules.

The Shippeo Carbon calculator follows the GLEC framework and is compliant with EN 16258 and GHG protocol.

Advanced container tracking over ocean
Major enhancements to Ocean Visibility will help supply chain and transport managers track and manage container shipments more productively, with new features and a revamped user experience, including:

  • More detailed container event information with new AIS-based milestones and precise geofencing
  • A revamped order detail page displaying all relevant container tracking information
  • Ability to identify deviations from status information provided by ocean carriers
  • An updated global map providing a holistic view of ocean shipments, by vessel or individual container
  • New filters making searching for containers easier
  • Higher overall data quality with inputs from new data sources

Road tracking enhancements
Timesaving usability enhancements, data quality improvements and ETA accuracy advancements are introduced for Road Visibility, offering customers an even more powerful over-the-road shipment tracking solution.

  • ETA accuracy improves 32% thanks to AI/ML algorithm advancements, upgraded Dataiku ML Ops platform infrastructure and data science methodology advancements
  • Shuttle flow tracking enables better differentiation between shipments within multiple back-and-forth tours for more accurate departure and arrival times
  • Quality Newsletters notify users of data tracking rates and provides steps for improving tracking quality
  • Improved visibility and readability of information, with new tagged events and links between map and timeline views

Infrastructure improvements to boost data quality and user experience
Shippeo’s platform has been migrated to Google Cloud Platform in its entirety, representing a major improvement in infrastructure. The shift ensures significant scalability, performance and localization capabilities along with enhanced security for customers.

Alongside the platform feature additions and enhancements, Shippeo has also continued to double-down on higher data quality, an area in which the company consistently leads the market. Continued investment of significant capital into R&D aims to advance the platform’s AI/ML capabilities even further.

To that point, the data warehouse powering Shippeo Insights is now migrated to Snowflake, a state-of-the-art high-performance analytics database that has managed to reduce Shippeo dashboard loading times by 50% on average and up to 90% for large customers.

About Shippeo
Shippeo, a global leader and European specialist in real-time transportation visibility, helps major shippers and logistics service providers leverage transportation to deliver exceptional customer service and achieve operational excellence. Their Multimodal Visibility Network connects FTL, LTL, parcel, and container transport and integrates 875+ TMS, telematics and ELD systems using a unique API. The Shippeo platform provides instant access to real-time delivery tracking, automates customer processes and offers unmatched ETA accuracy thanks to a proprietary and industry-leading algorithm developed in-house. Hundreds of customers, including global brands like Coca-Cola HBC, Carrefour, Renault Group, Schneider Electric, Total, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 28 million shipments per year across 75 countries. Learn more at

LinkedIn, Facebook, Twitter

To view this piece of content from, please give your consent at the top of this page.

Contact information

Europe: Andrea Krug, Krug Communications Ltd, Tel. +44 (0)7740 245 867, email:

North America: Carol Kraeutler Lerner, CKL Communications, Tel. +1 (201) 602-7572, email:

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CARVYKTI ® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma26.5.2022 09:10:00 CEST | Press release

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the European Commission (EC) has granted conditional marketing authorization of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. Legend Biotech entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc. (Janssen) to develop and commercialize cilta-cel in December 2017. CARVYKTI® is a chimeric antigen receptor T-cell (CAR-T) therapy featuring two B-cell maturation antigen (BCMA)-targeting single domain antibodies.1 CAR-T therapy is specifically developed

European Commission Grants Conditional Approval of CARVYKTI ® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma26.5.2022 09:00:00 CEST | Press release

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) granted conditional marketing authorisation of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. In December 2017, Janssen Biotech, Inc. (Janssen) entered into an exclusive worldwide license and collaboration agreement with Legend Biotech USA, Inc. to develop and commercialise cilta-cel.2 “Patients who have relapsed, or for whom treatment regimens have stopped working after experiencing the three major drug classes, typically face poor survival. Despite recent innovation, new therapeutic approaches are still needed,” said Maria-Victoria Mateos, M.D., Ph.D., Consultant Physician in Haematology,

SCREEN Increases Efforts to Reduce the Environmental Impact of the Semiconductor Industry26.5.2022 06:30:00 CEST | Press release

SCREEN Semiconductor Solutions Co., Ltd. (SCREEN SPE), a subsidiary of SCREEN Holdings Co., Ltd., has announced it will increase its efforts to reduce the company’s environmental overall impact. The SCREEN Group is committed to both achieving a sustainable global society and to improving its sustainable value (social value) and has formulated a medium-term management plan titled Sustainable Value 2023 targeting these goals. The plan identifies specific issues in each of the environmental, social, and governance (ESG) fields. Concerning the environment, SCREEN is working to provide products and services that actively contribute to the reduction of ecological burden. Its efforts include improving the environmental performance of its products, reducing the effects of its business activities on climate change, promoting effective utilization of water resources, increasing recycling of products and parts, and helping to preserve biodiversity. Concretely, SCREEN SPE seeks to reduce the impac

Lenovo Group: Full Year Financial Results 2021/2226.5.2022 06:19:00 CEST | Press release

Lenovo Group (HKSE: 992) (ADR: LNVGY) today announced record fiscal year results for the Group, with historic highs for both profit and revenue. Annual net income reached the US$2 billion mark, up 72% year on year, with revenue growing by US$10 billion for the second year running to over US$71 billion. All main business groups were profitable for the full fiscal year - with strong growth momentum in mobile, infrastructure, and solutions and services businesses. Lenovo successfully overcame macro-environmental challenges and demonstrated both agility and resilience as it navigated industry-wide supply shortages, pandemic disruption, geopolitical uncertainties, and higher inflation to deliver a record year. The digital and intelligent transformation trend continues to accelerate, presenting the Group with strong growth opportunities. More than 50% of companies now have digitalization as part of their corporate strategy, up from just over one third two years ago. The hybrid work model is

Exscientia Business Update for First Quarter 202225.5.2022 22:01:00 CEST | Press release

Exscientia plc (Nasdaq: EXAI) This press release features multimedia. View the full release here: Recent advancements in the Company’s pipeline, collaborations, and operations, as well as financial results for the first quarter 2022, are summarised below. In addition, Exscientia will host a conference call Thursday, May 26 at 1:30 p.m. BST / 8:30 a.m. ET to provide an overview of the Company's precision medicine platform. "We started 2022 by commencing a groundbreaking collaboration with Sanofi to develop a pipeline of AI-designed medicines utilising the breadth of our end-to-end platform of AI-driven capabilities from target prioritisation, to drug engineering and patient selection. At this year's American Association of Cancer Research (AACR) Annual Meeting, we highlighted our advancements in this area, including how AI-enabled drug design can help create drug candidates for challenging targets in oncology. In addition, we sho